Gene therapy, (Photo: Shutterstock.com)
Japan's second-largest drugmaker, Astellas, is buying San Francisco-based Audentes for about $3 billion in cash.
December 04, 2019 at 01:41 PM
1 minute read
Covington & Burling and Fenwick & West have landed the lead roles on a $3 billion Japanese pharmaceutical deal.
Japan’s second-largest drugmaker, Astellas Pharma Inc., has agreed to acquire San Francisco-based drugmaker Audentes Therapeutics Inc. for about $3 billion in cash. The transaction is expected to be completed in the first quarter of 2020, subject to regulatory approval, including U.S. antitrust clearance.
Presented by BigVoodoo
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
